SCHEMBL26313672

SCHEMBL26313672

CCC(CO)NCCN(C(=O)c1cc(Cl)ccc1C#N)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
ALDH1A1 P00352 5/20 0.37
TP53 P04637 1/20 0.37
CYP3A4 P08684 2/20 0.36
HTT P42858 2/20 0.36
MAPT P10636 2/20 0.36
APAF1 O14727 1/20 0.36
LTB4R2 Q9NPC1 1/20 0.36
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 1/20 0.35
F10 P00742 1/20 0.35
CYP2D6 P10635 3/20 0.34
SLC6A2 P23975 3/20 0.34
SLC6A4 P31645 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25411012 0.94 TSHR (0.41) TSHRALDH1A1TP53CYP3A4HTT
SCHEMBL26313667 0.83 TSHR (0.47) TSHRALDH1A1TP53CYP3A4HTT
SCHEMBL26313674 0.83 TSHR (0.43) TSHRALDH1A1TP53CYP3A4HTT
SCHEMBL26313653 0.82 TSHR (0.52) TSHRALDH1A1TP53CYP3A4HTT
SCHEMBL25412807 0.82 TSHR (0.42) TSHRALDH1A1TP53CYP3A4HTT
SCHEMBL26313981 0.82 TSHR (0.39) TSHRALDH1A1CYP3A4HTTRAB9A
SCHEMBL25411640 0.81 TSHR (0.44) TSHRALDH1A1TP53CYP3A4HTT
SCHEMBL26313663 0.81 TSHR (0.45) TSHRALDH1A1TP53CYP3A4HTT
SCHEMBL25413416 0.80 TSHR (0.41) TSHRALDH1A1TP53CYP3A4HTT
SCHEMBL26313671 0.79 NOS2 (0.42) ALDH1A1HTTMAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF Gacter Inc. (US) 2023-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF NOS1, NOS3, NOS2 TSHR 990/4885ALDH1A1 2994/4885TP53 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.